ABEO
Price
$6.89
Change
+$0.03 (+0.44%)
Updated
Sep 5 closing price
Capitalization
353.31M
72 days until earnings call
OCUL
Price
$13.60
Change
+$0.90 (+7.09%)
Updated
Sep 5 closing price
Capitalization
2.37B
65 days until earnings call
Interact to see
Advertisement

ABEO vs OCUL

Header iconABEO vs OCUL Comparison
Open Charts ABEO vs OCULBanner chart's image
Abeona Therapeutics
Price$6.89
Change+$0.03 (+0.44%)
Volume$536.78K
Capitalization353.31M
Ocular Therapeutix
Price$13.60
Change+$0.90 (+7.09%)
Volume$4.98M
Capitalization2.37B
ABEO vs OCUL Comparison Chart in %
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. OCUL commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and OCUL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ABEO: $6.89 vs. OCUL: $13.60)
Brand notoriety: ABEO and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 78% vs. OCUL: 225%
Market capitalization -- ABEO: $353.31M vs. OCUL: $2.37B
ABEO [@Biotechnology] is valued at $353.31M. OCUL’s [@Biotechnology] market capitalization is $2.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, ABEO is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 3 TA indicator(s) are bullish while OCUL’s TA Score has 4 bullish TA indicator(s).

  • ABEO’s TA Score: 3 bullish, 5 bearish.
  • OCUL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а +0.88% price change this week, while OCUL (@Biotechnology) price change was +11.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ABEO is expected to report earnings on Nov 17, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.37B) has a higher market cap than ABEO($353M). OCUL YTD gains are higher at: 59.251 vs. ABEO (23.698). ABEO has higher annual earnings (EBITDA): 80M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. ABEO (226M). ABEO has less debt than OCUL: ABEO (24.1M) vs OCUL (76.9M). OCUL has higher revenues than ABEO: OCUL (56.7M) vs ABEO (400K).
ABEOOCULABEO / OCUL
Capitalization353M2.37B15%
EBITDA80M-200.5M-40%
Gain YTD23.69859.25140%
P/E Ratio10.77N/A-
Revenue400K56.7M1%
Total Cash226M391M58%
Total Debt24.1M76.9M31%
FUNDAMENTALS RATINGS
ABEO vs OCUL: Fundamental Ratings
ABEO
OCUL
OUTLOOK RATING
1..100
7316
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
2098
PRICE GROWTH RATING
1..100
4739
P/E GROWTH RATING
1..100
56100
SEASONALITY SCORE
1..100
3975

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (56) in the Pharmaceuticals Other industry is in the same range as ABEO (81) in the Pharmaceuticals Generic industry. This means that OCUL’s stock grew similarly to ABEO’s over the last 12 months.

OCUL's Profit vs Risk Rating (79) in the Pharmaceuticals Other industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that OCUL’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's SMR Rating (20) in the Pharmaceuticals Generic industry is significantly better than the same rating for OCUL (98) in the Pharmaceuticals Other industry. This means that ABEO’s stock grew significantly faster than OCUL’s over the last 12 months.

OCUL's Price Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as ABEO (47) in the Pharmaceuticals Generic industry. This means that OCUL’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's P/E Growth Rating (56) in the Pharmaceuticals Generic industry is somewhat better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that ABEO’s stock grew somewhat faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOOCUL
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 18 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWDAX19.04N/A
N/A
Templeton World Adv
SCIZX7.57N/A
N/A
Virtus SGA International Growth R6
FIKAX50.22N/A
N/A
Fidelity Advisor Energy Z
FNCMX276.38N/A
N/A
Fidelity Nasdaq Composite Index
CETAX13.94N/A
N/A
Centerstone Investors A

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ZYME. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+0.44%
ZYME - ABEO
49%
Loosely correlated
+6.89%
CRNX - ABEO
43%
Loosely correlated
+3.97%
ELVN - ABEO
43%
Loosely correlated
+0.70%
OCUL - ABEO
42%
Loosely correlated
+7.09%
DYN - ABEO
42%
Loosely correlated
+7.40%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+7.09%
EYPT - OCUL
65%
Loosely correlated
+17.93%
RVMD - OCUL
55%
Loosely correlated
+3.98%
CRNX - OCUL
55%
Loosely correlated
+3.97%
IDYA - OCUL
55%
Loosely correlated
+5.15%
DNLI - OCUL
55%
Loosely correlated
+4.33%
More